Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer

International Journal of Molecular Sciences

Volumn 12, Issue 6, 2011, Pages 3489-3499

  Zeng, Hua Zong ^a   Qu, Yi Qing ^b   Zhang, Wen Jun ^c   Xiu, Bing ^c   Deng, An Mei ^d   Liang, Ai Bin ^c  

^a TONGJI UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; DJ 1; Non small lung cancer; Proteomics; Resistance

Indexed keywords

CISPLATIN; DJ 1 PROTEIN; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ADULT; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN A549; CELL STRAIN A549/DDP; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PROTEOMICS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UP-REGULATION;

EID: 79959748950     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12063489     Document Type: Article

References (16)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer statistics. CA Cancer J. Clin. 2002, 52, 23-47.
2. Sève, P.; Dumontet, C. Chemoresistance in non-small cell lung cancer. Curr. Med. Chem. Anticancer Agents 2005, 5, 73-88.
3. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J.M.; Provencio, M.; Viñolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Muñoz, M.A.; et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 2747-2754.
4. Kim, H.T.; Lee, J.E.; Shin, E.S.; Yoo, Y.K.; Cho, J.H.; Yun, M.H.; Kim, Y.H.; Kim, S.K.; Kim, H.J.; Jang, T.W.; et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J. Clin. Oncol. 2008, 26, 5972-5979.
5. Park, K.S.; Kim, H.K.; Lee, J.H.; Choi, Y.B.; Park, S.Y.; Yang, S.H.; Kim, S.Y.; Hong, K.M. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 493-502.
6. Gong, F.; Peng, X.; Zeng, Z.; Yu, M.; Zhao, Y.; Tong, A. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol. Cell. Biochem. 2011, 348, 141-147.
7. Li, S.L.; Ye, F.; Cai, W.J.; Hu, H.D.; Hu, P.; Ren, H.; Zhu, F.F.; Zhang, D.Z. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J. Cell. Biochem. 2010, 109, 625-633.
8. Yang, Y.; Gehrke, S.; Haque, M.E.; Imai, Y.; Kosek, J.; Yang, L.; Beal, M.F.; Nishimura, I.; Wakamatsu, K.; Ito, S.; Takahashi, R.; Lu, B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. USA 2005, 102, 13670-13675.
9. Vasseur, S.; Afzal, S.; Tardivel-Lacombe, J.; Park, D.S.; Iovanna, J.L.; Mak, T.W. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl. Acad. Sci. USA 2009, 106, 1111-1116.
10. Shinbo, Y.; Taira, T.; Niki, T.; Iguchi-Ariga, S.M.; Ariga, H. DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3. Int. J. Oncol. 2005, 26, 641-648.
11. Kim, R.H.; Peters, M.; Jang, Y.; Shi, W.; Pintilie, M.; Fletcher, G.C.; DeLuca, C.; Liepa, J.; Zhou, L.; Snow, B.; et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005, 7, 263-273.
12. Asechi, H.; Hatano, E.; Nitta, T.; Tada, M.; Iwaisako, K.; Tamaki, N.; Nagata, H.; Narita, M.; Yanagida, A.; Ikai, I.; Uemoto, S. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int. J. Oncol. 2010, 37, 89-96.
13. Peng, D.J.; Wang, J.; Zhou, J.Y.; Wu, G.S. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem. Biophys. Res. Commun. 2010, 394, 600-605.
14. Hao, J.; Song, X.; Song, B.; Liu, Y.; Wei, L.; Wang, X.; Yu, J. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 2008, 15, 449-455.
15. Huang, X.Z.; Wang, J.; Huang, C.; Chen, Y.Y.; Shi, G.Y.; Hu, Q.S.; Yi, J. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol. Ther. 2008, 7, 468-475.
16. Jeong, S.H.; Jung, J.H.; Han, J.H.; Kim, J.H.; Choi, Y.W.; Lee, H.W.; Kang, S.Y.; Hwang, Y.H.; Ahn, M.S.; Choi, J.H.; et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 2010, 68, 288-294.